返回
CervoMed Inc（CRVO）價格
CRVO 股價走勢圖
CRVO 財務
CervoMed Inc
$4.54
-3.81%
$-0.17
收盤價：Feb 17, 16:00:00 GMT-5
$4.75
4.62%
$0.2
盤前：Feb 18, 07:47:07 GMT-5
關鍵數據
前收市價
$4.72
開盤價
$4.75
當日範圍
$4.52 - $4.83
52週區間
$1.92 - $16.94
交易量
48.6K
平均成交量
72.6K
每股盈餘 (TTM)
-2.87
股息收益率
--
市值
$43.9M
什麼是 CRVO？
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.